NHS to Offer Immunotherapy Drug Pembrolizumab for Aggressive Cervical Cancer

New Treatment Option for Patients

The National Health Service (NHS) in England has confirmed that pembrolizumab, also known by the brand name Keytruda, will be made available to hundreds of women diagnosed with aggressive cervical cancer. This decision follows guidance from the National Institute for Health and Care Excellence (NICE), which recommended the drug for patients with persistent, recurrent, or metastatic cervical cancer whose tumors express a specific protein known as PD-L1.

How the Treatment Works

Pembrolizumab is an immunotherapy drug that works by helping the patient's own immune system identify and attack cancer cells. Under the new guidance, the drug will be administered in combination with chemotherapy, with or without the targeted therapy bevacizumab. Clinical trials have demonstrated that this combination can significantly extend the lives of patients compared to standard chemotherapy alone. NHS England's national director for cancer, Professor Peter Johnson, stated, 'This is a really important development for women with advanced cervical cancer, offering them more time with their families and loved ones.'

Impact on Patient Care

Cervical cancer is often diagnosed in younger women, and advanced stages of the disease have historically had limited treatment options. The introduction of pembrolizumab is expected to benefit approximately 300 to 400 women in England each year. By integrating this immunotherapy into the standard care pathway, the NHS aims to improve outcomes for those facing a difficult prognosis. The drug is administered via an intravenous infusion, typically every three to six weeks, depending on the specific treatment regimen.

Commitment to Cancer Innovation

This rollout is part of a broader effort by the NHS to provide faster access to cutting-edge cancer treatments. The inclusion of pembrolizumab highlights the health service's focus on utilizing immunotherapy to treat aggressive malignancies. Patients are encouraged to speak with their oncology teams to determine if they are eligible for this treatment based on their specific clinical profile and tumor characteristics.